PURPOSE: TGFBR16A is a tumor susceptibility gene that increases breast, colon, and ovarian cancer risk. Fourteen percent of the general population carries TGFBR16A, and TGFBR16A homozygotes have a greater than 100% increased colon cancer risk compared with noncarriers. Low-penetrance genes such as TGFBR16A may account for a sizable proportion of familial colorectal cancer occurrences. To test this hypothesis, we determined whether TGFBR16A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients. PATIENTS AND METHODS: A case-case study was performed of 208 index patients with HNPCC meeting the Amsterdam criteria. Patients were examined for mutations and genomic rearrangements in the MLH1, MSH2, and MSH6 genes and genotyped for TGFBR16A. Tumor microsatellite instability status was available for 95 patients. RESULTS: A total of 144 patients (69.2%) carried a deleterious mutation and were classified as positive for MMR gene mutation; 64 patients (30.8%) had no evidence of mutations and were classified as MMR negative. TGFBR16A allelic frequency was significantly higher among MMR-negative patients (0.195) than among MMR-positive patients (0.104; P = .011). The proportion of TGFBR16A homozygotes was nine-fold higher among MMR-negative (6.3%) than among MMR-positive patients (0.7%; P = .032). The highest TGFBR16A allelic frequency was found among MMR-negative patients with tumors exhibiting no microsatellite instability (0.211), and the lowest frequency was found among MMR-positive patients with tumors exhibiting microsatellite instability (0.121); the difference was not statistically significant (P = .17). CONCLUSION: TGFBR16A may be causally responsible for a proportion of HNPCC occurrences.
PURPOSE: TGFBR16A is a tumor susceptibility gene that increases breast, colon, and ovarian cancer risk. Fourteen percent of the general population carries TGFBR16A, and TGFBR16A homozygotes have a greater than 100% increased colon cancer risk compared with noncarriers. Low-penetrance genes such as TGFBR16A may account for a sizable proportion of familial colorectal cancer occurrences. To test this hypothesis, we determined whether TGFBR16A contributes to a proportion of mismatch repair (MMR) gene mutation-negative hereditary nonpolyposis colorectal cancer (HNPCC) patients. PATIENTS AND METHODS: A case-case study was performed of 208 index patients with HNPCC meeting the Amsterdam criteria. Patients were examined for mutations and genomic rearrangements in the MLH1, MSH2, and MSH6 genes and genotyped for TGFBR16A. Tumor microsatellite instability status was available for 95 patients. RESULTS: A total of 144 patients (69.2%) carried a deleterious mutation and were classified as positive for MMR gene mutation; 64 patients (30.8%) had no evidence of mutations and were classified as MMR negative. TGFBR16A allelic frequency was significantly higher among MMR-negative patients (0.195) than among MMR-positive patients (0.104; P = .011). The proportion of TGFBR16A homozygotes was nine-fold higher among MMR-negative (6.3%) than among MMR-positive patients (0.7%; P = .032). The highest TGFBR16A allelic frequency was found among MMR-negative patients with tumors exhibiting no microsatellite instability (0.211), and the lowest frequency was found among MMR-positive patients with tumors exhibiting microsatellite instability (0.121); the difference was not statistically significant (P = .17). CONCLUSION: TGFBR16A may be causally responsible for a proportion of HNPCC occurrences.
Authors: Moubin Lin; David J Stewart; Margaret R Spitz; Michelle A T Hildebrandt; Charles Lu; Jie Lin; Jian Gu; Maosheng Huang; Scott M Lippman; Xifeng Wu Journal: Carcinogenesis Date: 2011-04-22 Impact factor: 4.944
Authors: Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle Journal: Cancer Biomark Date: 2010 Impact factor: 4.388
Authors: Rosa M Xicola; Sneha Bontu; Brian J Doyle; Jamie Rawson; Pilar Garre; Esther Lee; Miguel de la Hoya; Xavier Bessa; Joan Clofent; Luis Bujanda; Francesc Balaguer; Sergi Castellví-Bel; Cristina Alenda; Rodrigo Jover; Clara Ruiz-Ponte; Sapna Syngal; Montserrat Andreu; Angel Carracedo; Antoni Castells; Polly A Newcomb; Noralane Lindor; John D Potter; John A Baron; Nathan A Ellis; Trinidad Caldes; Xavier LLor Journal: Carcinogenesis Date: 2016-05-27 Impact factor: 4.944
Authors: Qinghua Zeng; Sharbani Phukan; Yanfei Xu; Maureen Sadim; Diana S Rosman; Michael Pennison; Jie Liao; Guang-Yu Yang; Chiang-Ching Huang; Laura Valle; Antonio Di Cristofano; Albert de la Chapelle; Boris Pasche Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: Laura Valle; Tarsicio Serena-Acedo; Sandya Liyanarachchi; Heather Hampel; Ilene Comeras; Zhongyuan Li; Qinghua Zeng; Hong-Tao Zhang; Michael J Pennison; Maureen Sadim; Boris Pasche; Stephan M Tanner; Albert de la Chapelle Journal: Science Date: 2008-08-14 Impact factor: 47.728
Authors: J Skoglund Lundin; J Vandrovcova; B Song; X Zhou; M Zelada-Hedman; B Werelius; R S Houlston; A Lindblom Journal: Br J Cancer Date: 2009-04-28 Impact factor: 7.640